新型SSTR靶向肽[18F]SiTATE用于分化型与髓样甲状腺癌PET/CT显像的首次临床经验
在一项单中心前瞻性观察研究中,21例经组织学证实的甲状腺癌患者(10例髓样癌、11例分化型癌)共接受37次[18F]SiTATE PET/CT检查,分析89个病灶。骨与淋巴结转移灶摄取值最高,髓样癌的PET肿瘤负荷与降钙素水平显著相关(如TTV:r=0.771,r²=0.594,p=0.002),分化型癌则无此相关性。作者认为[18F]SiTATE PET/CT在甲状腺癌中具有高可行性,可能克服68Ga标记示踪剂的物流不便。
要点
- 21例甲状腺癌患者(10例髓样癌、11例分化型癌)共行37次[18F]SiTATE PET/CT,分析89个病灶。
- 骨转移(31个病灶,SUVmax 8.6±8.0)与淋巴结转移(37个病灶,SUVmax 8.7±7.8)摄取值最高。
- 髓样癌PET肿瘤负荷与降钙素显著相关(TTV:r=0.771,p=0.002),分化型癌无此相关性。
核心结论
- 数据表明[18F]SiTATE PET/CT在小型髓样癌与分化型甲状腺癌队列中具有高可行性。
- 作者认为[18F]SiTATE可能克服68Ga标记示踪剂的物流不便,并促进甲状腺癌的SSTR靶向PET/CT显像。
研究设计与样本
- 单中心前瞻性观察研究,纳入21例经组织学证实的甲状腺癌患者(10例髓样癌、11例分化型癌),共37次[18F]SiTATE PET/CT检查,分析89个病灶。
- 测定肿瘤病灶的平均SUVmax与SUVmean、平均总肿瘤体积(TTV)及全身WB-SUVmax与WB-SUVmean及其标准差,并将PET参数与肿瘤标志物水平(分化型癌为甲状腺球蛋白、髓样癌为降钙素)进行相关性分析。
主要发现
- 转移灶位于骨、淋巴结、肺、软组织及甲状腺床。
- 骨转移(31个病灶)SUVmax 8.6±8.0、SUVmean 5.8±5.4;淋巴结转移(37个病灶)SUVmax 8.7±7.8、SUVmean 5.7±5.4,两者摄取值最高。
- 髓样癌PET肿瘤负荷与降钙素水平显著相关(例如TTV:r=0.771,r²=0.594,p=0.002)。
- 分化型甲状腺癌中未观察到上述相关性。
关键数值与推荐
- 髓样癌PET肿瘤负荷与降钙素相关:TTV的r=0.771、r²=0.594、p=0.002。
- 骨转移31个病灶SUVmax 8.6±8.0、SUVmean 5.8±5.4;淋巴结转移37个病灶SUVmax 8.7±7.8、SUVmean 5.7±5.4。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究为单中心前瞻性观察研究。
- 作者称其为小型队列(small cohort)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The novel 18F-labeled somatostatin receptor (SSTR)-directed radiotracer [18F]SiTATE demonstrated promising results for the imaging of various SSTR-expressing tumor types. Although thyroid carcinomas (TC) express SSTR, data on [18F]SiTATE PET/CT imaging in TC are lacking. This study explores the use of [18F]SiTATE PET/CT in a patient cohort with histologically proven TC. METHODS: As part of a prospective observational study at a single tertiary cancer center, 21 patients with TC (10 medullary (MTC) and 11 differentiated (DTC)) who underwent at least one [18F]SiTATE PET/CT were included (37 scans in total). Mean SUVmax and SUVmean of tumoral lesions, mean total-tumor-volume (TTV), and whole-body (WB)-SUVmax and WB-SUVmean on PET with their standard deviations (SDs) were determined. PET parameters were correlated to clinical parameters including tumor marker levels (thyroglobulin for DTC, calcitonin for MTC). RESULTS: 89 lesions were included in the analysis. Metastases were localized in the bone, lymph nodes, lung, soft tissue, and thyroid bed. Osseous (31 lesions; SUVmax 8.6 ± 8.0; SUVmean 5.8 ± 5.4) and nodal (37 lesions; SUVmax 8.7 ± 7.8; SUVmean 5.7 ± 5.4) metastases showed the highest uptake. The MTC disease burden on PET significantly correlated with the calcitonin tumor marker level (e.g., TTV: r = 0.771, r2 = 0.594, p = 0.002). For DTC, no such correlation was present. CONCLUSION: Our data demonstrate high feasibility of [18F]SiTATE PET/CT in a small cohort of patients with MTC and DTC. The use of [18F]SiTATE may overcome logistical disadvantages of 68Ga-based tracers and facilitate SSTR-targeted PET/CT imaging of thyroid carcinoma.
引用
- Kunte SC, Wenter V, Toms J, et al. PET/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [18F]SiTATE - first clinical experiences. Eur J Nucl Med Mol Imaging. 2024. PMID: 39404789. doi:10.1007/s00259-024-06944-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。